Literature DB >> 9482537

The effects of interferon-alpha on the production and action of other cytokines.

J L Taylor1, S E Grossberg.   

Abstract

Various interferon-alpha (IFN-alpha) preparations, either as individual subtypes or natural mixtures, induce or inhibit expression of several other cytokines, as well as cytokine receptors and chemokines. The cytokines and receptors reportedly affected by IFN-alpha include interleukin-1 (IL-1), IL-2, IL-6, IL-8, IL-1 receptor, IL-1 receptor antagonist, tumor necrosis factor, tumor necrosis factor receptor, and IFN-gamma, all of which may amplify the effects of IFN-alpha treatment. The mechanism by which IFN-alpha induces expression of these cytokines is not clear. Some of the therapeutic and toxic effects associated with IFN-alpha therapy may be caused by the induction or inhibition of other cytokines and their respective cellular effects. Side effects including fever, anorexia, and fatigue can be caused by one or more of the cytokines induced by IFN-alpha. The response of different cell types, normal or malignant, to cytokines can vary. Such variation in cell type-specific responses may contribute to the diverse array of physiologic effects associated with IFN-alpha therapy. Further research is required to systematically uncover how other cytokines, receptors, or cellular factors contribute to the therapeutic and toxic effects of IFN-alpha.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9482537

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  34 in total

1.  Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol.

Authors:  Charles L Raison; David B Rye; Bobbi J Woolwine; Gerald J Vogt; Breanne M Bautista; James R Spivey; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2010-05-26       Impact factor: 13.382

2.  Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating polyneuropathy.

Authors:  Giovanni Pavesi; Luigi Cattaneo; Adriana Marbini; Franco Gemignani; Domenico Mancia
Journal:  J Neurol       Date:  2002-06       Impact factor: 4.849

3.  Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression.

Authors:  Jennifer C Felger; Oyetunde Alagbe; Fang Hu; Deborah Mook; Amanda A Freeman; Mar M Sanchez; Ned H Kalin; Emiliangelo Ratti; Charles B Nemeroff; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2007-08-02       Impact factor: 13.382

4.  Association of plasma adiponectin concentrations with chronic lymphocytic leukemia and myeloproliferative diseases.

Authors:  Ferit Avcu; A Ugur Ural; M Ilker Yilmaz; Necati Bingol; Oral Nevruz; Kayser Caglar
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

Review 5.  Potential role of type I interferons in the treatment of pituitary adenomas.

Authors:  Giovanni Vitale; Michele Caraglia; Peter M van Koetsveld; Paola Maroni; Monica Marra; Annamaria Colao; Steven W J Lamberts; Francesco Cavagnini; Leo J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2008-07-06       Impact factor: 6.514

6.  Effect of Ondansetron, a 5-HT(3) receptor antagonist, on fatigue in 2 veterans with hepatitis C.

Authors:  Dimitre H Dimitrov
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

Review 7.  A critical review of human endotoxin administration as an experimental paradigm of depression.

Authors:  Nicole DellaGioia; Jonas Hannestad
Journal:  Neurosci Biobehav Rev       Date:  2009-08-08       Impact factor: 8.989

8.  Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression.

Authors:  Charles L Raison; Andrey S Borisov; Matthias Majer; Daniel F Drake; Giuseppe Pagnoni; Bobbi J Woolwine; Gerald J Vogt; Breanne Massung; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2008-09-18       Impact factor: 13.382

Review 9.  Immune system to brain signaling: neuropsychopharmacological implications.

Authors:  Lucile Capuron; Andrew H Miller
Journal:  Pharmacol Ther       Date:  2011-02-17       Impact factor: 12.310

Review 10.  Cytokines and glucocorticoid receptor signaling. Relevance to major depression.

Authors:  Thaddeus W W Pace; Andrew H Miller
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.